GlaxoSmithKline Pakistan Limited

GLAXO

PK0001301016

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
135.8 ^PKR	+3.10%		+9.65%	+63.69%

01/04	GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

GlaxoSmithKline Pakistan Limited Announces Board Changes

April 02, 2020 at 10:32 pm IST

GlaxoSmithKline Pakistan Limited announced that Mr. Muneer Kamal has been appointed as Non-Executive Officer of the company with effect from April 02, 2020 in place of Mr. Sohail Ahmed.

Latest news about GlaxoSmithKline Pakistan Limited

GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/23/31	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Glaxosmithkline Pakistan Limited Announces Change of Company Secretary	02/23/02	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	03/23/03	CI
GlaxoSmithKline Pakistan Limited Announces Board Changes	10/22/10	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	02/22/02	CI
Glaxosmithkline Pakistan Limited Appoints Simon Forster as Director	28/22/28	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	01/22/01	CI
Glaxo Smith Kline Pakistan Limited Appoints Lai Kuen Goh as Director	12/22/12	CI
GlaxoSmithKline Pakistan Limited Announces Board Changes	10/22/10	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	02/22/02	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	04/22/04	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	25/21/25	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	23/21/23	CI
Glaxosmithkline Pakistan Limited Announces Board Changes	02/21/02	CI
Glaxosmithkline Pakistan Limited Announces Executive Changes	02/21/02	CI
GlaxoSmithKline Pakistan Limited Approves Final Cash Dividend for the Year Ended December 31, 2020	10/21/10	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	10/21/10	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	28/20/28	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	24/20/24	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	15/20/15	CI
GlaxoSmithKline Pakistan Limited Announces Board Changes	02/20/02	CI
Glaxosmithkline Pakistan Limited Recommends Final Cash Dividend for the Year Ended Dec. 31, 2019	11/20/11	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	11/20/11	CI

Chart GlaxoSmithKline Pakistan Limited

Duration

Period

More charts

GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, including but not limited to psoriasis, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAXOSMITHKLINE PAKISTAN LIMITED	+63.69%	15Cr
ELI LILLY AND COMPANY	+33.10%	71TCr
NOVO NORDISK A/S	+30.77%	60TCr
JOHNSON & JOHNSON	-1.82%	37TCr
MERCK & CO., INC.	+20.17%	33TCr
ABBVIE INC.	+5.78%	29TCr
ASTRAZENECA PLC	+14.77%	24TCr
NOVARTIS AG	+9.13%	21TCr
ROCHE HOLDING AG	-3.97%	20TCr
AMGEN INC.	+9.22%	17TCr

Other Pharmaceuticals